C60 has incredibly powerful antioxidant properties, leading to high demand for its use as a daily supplement. Strong antioxidants help with the prevention of metabolic and neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, cancer, heart disease, and diabetes.
RESEARCH & DEVELOPMENT
Clinical Trials
UC San Diego Department
of Neurosciences
The trial topic: Parkinson
University of Pittsburgh
Medical Center
The trial topic: about cancers
Western University of
Health Sciences
The trial topic: Alzheimer’s & Anti-viral
On-going Projects
Toxicity Tests: Western University: Category III safety
Genotoxicity 3:
Trial time: 3~4 months
Toxicity Trial: for 90 days
Trial Duration: 6 months
Teratogenic fetal test: 6 months trial time
Lab tests started in Dec. 2022
US FDA: NDI (New Dietary Ingredients) Application Register: Applied in Dec, 2022
(Waiting for Toxicity Test results to submit the report to FDA)
Patents
Trusted By Experts
Technological Background
The technology behind C60 MD products originates from the U.S. company SINAPU LLC CORPORATION, led by Simon Cao and Dr. Butzloff. Their unique technology derives from Richard Smalley, the father of carbon nanotubes, and combines quantum physics and nanotechnology to develop water-soluble C60 (fullerenol), greatly enhancing oral bioavailability (BA). This technology gives C60 nano-drug delivery capabilities, allowing it to penetrate the blood-brain barrier (BBB) and treat brain-related diseases such as Parkinson's, Alzheimer's, and dementia. These significant breakthroughs make water-soluble C60 highly promising for future preventive medicine and health applications.